The Clinuvel Pharmaceuticals Ltd (ASX: CUV) share price is in focus after the company posted its tenth straight annual profit and announced a stable, fully franked dividend of $0.05 per share for FY2026.
What did Clinuvel Pharmaceuticals report?
- Revenue declined slightly to $94.0 million, down 1% from FY2025.
- Net profit after tax was $33.9 million, a 6% decrease year on year.
- Cash reserves rose 12% to $252.1 million.
- Expenses held steady, dropping 0.5% to $53.5 million.
- Basic earnings per share slipped 6% to $0.68.
- A franked final dividend of $0.05 per share was declared, matching last year.
What else do investors need to know?
Clinuvel’s profit marks a decade of uninterrupted earnings, which the company credits to disciplined cost controls and strong treatment demand for SCENESSE®. While revenue declined marginally as US sales softened â partly due to competitor programs and a shift in US supply practices â European revenue growth offset this impact.
The balance sheet remains robust, with net tangible assets per share climbing 12%. Operating cash inflow was $36.9 million, and after prepaying income tax, cash reserves still finished notably higher. The steady dividend reflects a commitment to reward shareholders, equating to 9% of free cash generated for the period.
What did Clinuvel Pharmaceuticals management say?
Group Chief Financial Officer Mr Peter Vaughan said:
This position provides us with flexibility to pursue an expansion strategy, continue investing through market cycles in key strategic areas, and allocate capital based on opportunity rather than necessity. As CLINUVEL builds its operations and presence in the capital markets in the United States, we can do so from a position of strength.
What’s next for Clinuvel Pharmaceuticals?
Clinuvel aims to use its strong cash and asset base to drive further growth in North America and other markets. Management will continue to invest in core areas like R&D and the Phase III vitiligo program and expects steady business expansion through diversification.
The company remains confident in self-financing its strategy, thanks to disciplined spending and consistent cash flow. Shareholders can also look forward to continued dividends, subject to cash reserves and performance.
Clinuvel Pharmaceuticals share price snapshot
Over the past 12 months, Clinuvel Pharmaceuticals shares have declined 31%, trailing the All Ordinaries Index (ASX: XAO), which is flat over the same period.
The post Clinuvel Pharmaceuticals posts 10th consecutive profit and maintains dividend appeared first on The Motley Fool Australia.
Should you invest $1,000 in Clinuvel Pharmaceuticals right now?
Before you buy Clinuvel Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Clinuvel Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares
- Corporate Travel Management reports FY25 and 1HY26 earnings
- Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses
- Why is the ASX 200 falling to a 4-day low today?
- Do leading brokers rate Woolworths shares as a buy following its results?
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.